Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.
Restore Vision has raised $8.2M in total funding. The most recent round was Series B. The last funding was announced in April 2026.
Restore Vision's investors include ANRI, JIC Venture Growth Investments, SMBC Venture Capital, UntroD Capital, Kyoto University Innovation Capital.
Restore Vision is headquartered in Tokyo, Japan.
Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.
Restore Vision is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Restore Vision — Funding & Investors." VCBacked, April 15, 2026, https://www.vcbacked.co/company/restore-vision. Accessed November 12, 2026.
VCBacked. (2026). Restore Vision — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/restore-vision
{{cite web |title=Restore Vision — Funding & Investors |url=https://www.vcbacked.co/company/restore-vision |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Restore Vision? Request a listing update